Anti-inflammatory effects of α-tocopherol

Uma Singh, Ishwarlal Jialal

Research output: Contribution to journalArticle

76 Citations (Scopus)

Abstract

Cardiovascular disease (CVD) is the leading cause of morbidity and mortality in the western world. Its incidence has been increasing lately in the developing countries. Much evidence suggests a major role for inflammation in all phases of atherosclerosis. Cell adhesion molecules, cytokines, chemokines, and monocytes-macrophages as well as T lymphocytes play a pivotal role in atherogenesis. C-reactive protein (CRP), a downstream marker of inflammation, in addition to being a risk marker for CVD, could contribute to atherosclerosis. Dietary micronutrients with anti-inflammatory properties, specially α-tocopherol, may play an important role with regard to the prevention and treatment of CVD. α-Tocopherol has been shown to have anti-inflammatory effects both in vitro and in vivo. α-Tocopherol therapy, especially at high doses, has been shown to decrease release of pro-inflammatory cytokines (such as interleukin-1β, interleukin-6, and tumor necrosis factor-α) and the chemokine interleukin-8, and to decrease adhesion of monocytes to endothelium. In addition, α-tocopherol has been shown to decrease CRP levels in patients with CVD and having related risk factors for CVD (such as diabetes and smoking). Furthermore, pro-inflammatory cytokines and plasminogen activator inhibitor-1 (PAI-1) levels have also been shown to be decreased with α-tocopherol supplementation in vivo. In this review, our focus will be on anti-inflammatory effects of α-tocopherol reported in in vivo studies.

Original languageEnglish (US)
Pages (from-to)195-203
Number of pages9
JournalAnnals of the New York Academy of Sciences
Volume1031
DOIs
StatePublished - 2004

Fingerprint

Tocopherols
Anti-Inflammatory Agents
Cardiovascular Diseases
Atherosclerosis
Cytokines
Chemokines
C-Reactive Protein
Monocytes
Inflammation
Western World
T-cells
Macrophages
Micronutrients
Plasminogen Activator Inhibitor 1
Cell Adhesion Molecules
Medical problems
Interleukin-8
Interleukin-1
Developing countries
Developing Countries

Keywords

  • α-tocopherol
  • C-reactive protein
  • Cardiovascular disease
  • Cytokines
  • Inflammation
  • Monocytes

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Anti-inflammatory effects of α-tocopherol. / Singh, Uma; Jialal, Ishwarlal.

In: Annals of the New York Academy of Sciences, Vol. 1031, 2004, p. 195-203.

Research output: Contribution to journalArticle

Singh, Uma ; Jialal, Ishwarlal. / Anti-inflammatory effects of α-tocopherol. In: Annals of the New York Academy of Sciences. 2004 ; Vol. 1031. pp. 195-203.
@article{82cfcc1386264ebdb15f121a9087fa30,
title = "Anti-inflammatory effects of α-tocopherol",
abstract = "Cardiovascular disease (CVD) is the leading cause of morbidity and mortality in the western world. Its incidence has been increasing lately in the developing countries. Much evidence suggests a major role for inflammation in all phases of atherosclerosis. Cell adhesion molecules, cytokines, chemokines, and monocytes-macrophages as well as T lymphocytes play a pivotal role in atherogenesis. C-reactive protein (CRP), a downstream marker of inflammation, in addition to being a risk marker for CVD, could contribute to atherosclerosis. Dietary micronutrients with anti-inflammatory properties, specially α-tocopherol, may play an important role with regard to the prevention and treatment of CVD. α-Tocopherol has been shown to have anti-inflammatory effects both in vitro and in vivo. α-Tocopherol therapy, especially at high doses, has been shown to decrease release of pro-inflammatory cytokines (such as interleukin-1β, interleukin-6, and tumor necrosis factor-α) and the chemokine interleukin-8, and to decrease adhesion of monocytes to endothelium. In addition, α-tocopherol has been shown to decrease CRP levels in patients with CVD and having related risk factors for CVD (such as diabetes and smoking). Furthermore, pro-inflammatory cytokines and plasminogen activator inhibitor-1 (PAI-1) levels have also been shown to be decreased with α-tocopherol supplementation in vivo. In this review, our focus will be on anti-inflammatory effects of α-tocopherol reported in in vivo studies.",
keywords = "α-tocopherol, C-reactive protein, Cardiovascular disease, Cytokines, Inflammation, Monocytes",
author = "Uma Singh and Ishwarlal Jialal",
year = "2004",
doi = "10.1196/annals.1331.019",
language = "English (US)",
volume = "1031",
pages = "195--203",
journal = "Annals of the New York Academy of Sciences",
issn = "0077-8923",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Anti-inflammatory effects of α-tocopherol

AU - Singh, Uma

AU - Jialal, Ishwarlal

PY - 2004

Y1 - 2004

N2 - Cardiovascular disease (CVD) is the leading cause of morbidity and mortality in the western world. Its incidence has been increasing lately in the developing countries. Much evidence suggests a major role for inflammation in all phases of atherosclerosis. Cell adhesion molecules, cytokines, chemokines, and monocytes-macrophages as well as T lymphocytes play a pivotal role in atherogenesis. C-reactive protein (CRP), a downstream marker of inflammation, in addition to being a risk marker for CVD, could contribute to atherosclerosis. Dietary micronutrients with anti-inflammatory properties, specially α-tocopherol, may play an important role with regard to the prevention and treatment of CVD. α-Tocopherol has been shown to have anti-inflammatory effects both in vitro and in vivo. α-Tocopherol therapy, especially at high doses, has been shown to decrease release of pro-inflammatory cytokines (such as interleukin-1β, interleukin-6, and tumor necrosis factor-α) and the chemokine interleukin-8, and to decrease adhesion of monocytes to endothelium. In addition, α-tocopherol has been shown to decrease CRP levels in patients with CVD and having related risk factors for CVD (such as diabetes and smoking). Furthermore, pro-inflammatory cytokines and plasminogen activator inhibitor-1 (PAI-1) levels have also been shown to be decreased with α-tocopherol supplementation in vivo. In this review, our focus will be on anti-inflammatory effects of α-tocopherol reported in in vivo studies.

AB - Cardiovascular disease (CVD) is the leading cause of morbidity and mortality in the western world. Its incidence has been increasing lately in the developing countries. Much evidence suggests a major role for inflammation in all phases of atherosclerosis. Cell adhesion molecules, cytokines, chemokines, and monocytes-macrophages as well as T lymphocytes play a pivotal role in atherogenesis. C-reactive protein (CRP), a downstream marker of inflammation, in addition to being a risk marker for CVD, could contribute to atherosclerosis. Dietary micronutrients with anti-inflammatory properties, specially α-tocopherol, may play an important role with regard to the prevention and treatment of CVD. α-Tocopherol has been shown to have anti-inflammatory effects both in vitro and in vivo. α-Tocopherol therapy, especially at high doses, has been shown to decrease release of pro-inflammatory cytokines (such as interleukin-1β, interleukin-6, and tumor necrosis factor-α) and the chemokine interleukin-8, and to decrease adhesion of monocytes to endothelium. In addition, α-tocopherol has been shown to decrease CRP levels in patients with CVD and having related risk factors for CVD (such as diabetes and smoking). Furthermore, pro-inflammatory cytokines and plasminogen activator inhibitor-1 (PAI-1) levels have also been shown to be decreased with α-tocopherol supplementation in vivo. In this review, our focus will be on anti-inflammatory effects of α-tocopherol reported in in vivo studies.

KW - α-tocopherol

KW - C-reactive protein

KW - Cardiovascular disease

KW - Cytokines

KW - Inflammation

KW - Monocytes

UR - http://www.scopus.com/inward/record.url?scp=14944383724&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=14944383724&partnerID=8YFLogxK

U2 - 10.1196/annals.1331.019

DO - 10.1196/annals.1331.019

M3 - Article

C2 - 15753145

AN - SCOPUS:14944383724

VL - 1031

SP - 195

EP - 203

JO - Annals of the New York Academy of Sciences

JF - Annals of the New York Academy of Sciences

SN - 0077-8923

ER -